

## II. LISTING OF THE CLAIMS:

### Listing of Claims:

1-37. (cancelled)

38. (previously presented) A method of effectively treating pain in humans or other mammals, comprising administering to a patient a dosage form comprising an analgesic combination consisting essentially of N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof.

39. (previously presented) The method of claim 38, wherein the dosage form is administered orally.

40-45. (cancelled)

46. (previously presented) The method of claim 38, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 2.5 mg to about 800 mg.

47. (previously presented) The method of claim 38, wherein the ratio of oxycodone and/or at least one pharmaceutically acceptable salt thereof to N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof is from about 0.001:1 to about 10:1.

48. (previously presented) The method of claim 38, wherein the oxycodone is present in the pharmaceutically acceptable salt form.

49. (previously presented) The method of claim 38, wherein the dosage form further comprises a sustained release carrier which provides a sustained release of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.

50. (previously presented) The method of claim 38, wherein the dosage form further comprises a sustained release carrier which provides a sustained release of the N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof.